Novo, Johnson and Johnson, Eli Lilly and Novartis are all participants in the neurodegenerative disease drug developer's first funding round.
US-based neurodegenerative disease therapy developer E-Scape Bio closed a $63m series A round yesterday that included pharmaceutical firms Novo, Johnson and Johnson, Eli Lilly and Novartis.
Novo, Johnson & Johnson Innovation – JJDC and Novartis Venture Fund, respective subsidiaries of Johnson and Johnson and Novartis, provided the first $55m of the funding along with Osage University Partners and OrbiMed.
A securities filing suggests the $20m first tranche of the round closed in August 2015. Lilly Asia Ventures, a corporate venturing…
